Treatment of headache (on one side of head) with Unani medicine Capsule Shaqiqa
- Conditions
- Health Condition 1: G439- Migraine, unspecified
- Registration Number
- CTRI/2021/06/034390
- Lead Sponsor
- Central Council for Research in Unani Medicine CCRUM New Delhi
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
1. Patients of either gender in the age group 18- 65 years
2. Primary diagnosis of Migraine without aura by ICHD-3 beta as follows:
A. At least five attacks fulfilling criteria Bâ??D.
B. Headache attacks lasting 4-72 hours (untreated or unsuccessfully treated).
C. Headache has at least two of the following four characteristics:
Unilateral location
Pulsating quality
Moderate or severe pain intensity
Aggravation by or causing avoidance ofroutine
physical activity (e.g. walking or climbing stairs).
D. During headache at least one of the following:
1. Nausea and/or vomiting.
2. Photophobia and phonophobia.
E. Not better accounted for by another ICHD-3diagnosis.
1. Known case of any structural brain abnormalities
2. Known case of Ocular disease
3. History of Ischaemic stroke
4. Any disease involving sinus e.g. Rhinosinusitis
5. Systemic illness requiring long term treatment
6. Known cases of Chronic kidney & liver disease
7. Known cases of Psychiatric illness
8. Difficulty distinguishing migraine headache from other headaches
9. Known cases of Epilepsy and other neurological disorders
10. History of alcohol and drug abuse.
11. Pregnancy & lactation
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Improvement in signs and symptoms of Shaqiqa (Migraine)Timepoint: The patients will be assessed clinically at baseline and at every two weeks till the completion of the trial i.e. upto 12 weeks
- Secondary Outcome Measures
Name Time Method Haematological and biochemical assessment for safety assessmentTimepoint: At baseline and at every two weeks till the completion of the trial i.e. upto 12 weeks